Aprocitentan in the treatment of resistant arterial hypertension: promising possibilities of endothelin-oriented therapy. Review
Ukrainian Therapeutical Journal · 31.03.2026 · (1) · 43-49
DOI: 10.30978/utj2026-1-43 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ukrainian Therapeutical Journal, online erschienen am 31.03.2026. Verfasst von I. P. Dunaieva und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Resistant arterial hypertension (RAH) remains one of the most challenging clinical problems in modern cardiology, especially among patients with concomitant type 2 diabetes mellitus, obesity, and chronic kidney disease (CKD). Despite the use of standard combination treatment regimens, a significant proportion of patients fail to achieve target blood pressure (BP) levels, thereby elevating cardiovascular and nephrological risk. Excessive activation of the endothelin system, particularly endothelin‑1, plays a crucial role in the pathogenesis of RAH by promoting vasoconstriction, sodium retention, vascular remodelling, and progression of target organ damage. Aprocitentan, the first dual endothelin receptor (ETA and ETB ) antagonist approved for the treatment of RAH, introduces new opportunities for targeted pathogenetic therapy. This article summarises current data on the mechanisms of action, pharmacological properties, clinical efficacy, and safety of aprocitentan based on findings from the multicenter PRECISION trial. Aprocitentan has been shown to provide a sustained and clinically significant reduction in BP, including in elderly patients and those with CKD, with an acceptable safety profile. Thus, aprocitentan is considered a promising alternative or adjunct to standard treatment strategies for RAH, with potential cardio‑ and nephroprotective properties, paving the way for personalised antihypertensive therapy. Further long‑term real‑world studies are warranted to confirm its impact on cardiovascular risk and renal disease progression. Incorporation of endothelin receptor antagonism into contemporary treatment algorithms may significantly enhance risk stratification and optimisation of therapy in patients with true resistant hypertension, particularly in high‑risk multimorbid populations.
Zitieren
APA
Dunaieva, I. P., Kravchun, P. P., Kryvoshapka, O. V., Pautina, O. I., & Doroshenko, O. M. (2026). Aprocitentan in the treatment of resistant arterial hypertension: promising possibilities of endothelin-oriented therapy. Review. Ukrainian Therapeutical Journal, 43-49. https://doi.org/10.30978/utj2026-1-43
Vancouver
Dunaieva IP, Kravchun PP, Kryvoshapka OV, Pautina OI, Doroshenko OM. Aprocitentan in the treatment of resistant arterial hypertension: promising possibilities of endothelin-oriented therapy. Review. Ukrainian Therapeutical Journal. 2026:43-49. doi:10.30978/utj2026-1-43
BibTeX
@article{Dunaieva2026,
author = {Dunaieva, I. P. and Kravchun, P. P. and Kryvoshapka, O. V. and Pautina, O. I. and Doroshenko, O. M.},
title = {Aprocitentan in the treatment of resistant arterial hypertension: promising possibilities of endothelin-oriented therapy. Review},
journal = {Ukrainian Therapeutical Journal},
year = {2026},
number = {1},
pages = {43--49},
doi = {10.30978/utj2026-1-43}
}
EUVIMED